HTG Molecular Diagnostics Announces Specific Preliminary 2020 Unaudited Economical Results

Preliminary comprehensive 12 months 2020 unaudited earnings of $8.5 million

Funds, cash equivalents and shorter-expression marketable securities of $28.7 million as of December 31, 2020

TUCSON, Ariz., Jan. 05, 2021 (World NEWSWIRE) —  HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a lifetime science organization whose mission is to progress precision medicine, these days announced specific preliminary, unaudited economic final results for the 12 months ended December 31, 2020.

Full profits for the full calendar year 2020 is envisioned to be around $8.5 million. Money, funds equivalents and small-term marketable securities are expected to be roughly $28.7 million as of December 31, 2020.

“Obviously COVID-19 impacted our core oncology business enterprise as prepared experiments were delayed and operations in a lot of of our customers’ laboratories were suspended or significantly curtailed,” said John Lubniewski, CEO of HTG. “In spite of these troubles, we noticed returning power in our main small business in the second half and especially in the fourth quarter of 2020. We successfully highly developed our approaches to improve shopper diversification into more compact and mid-sized biopharma corporations and develop small business with substantial, tutorial health care centers. In addition, we expanded our current market arrive at outside of oncology into immune reaction, gaining various new clients and courses in the fourth quarter. Though we are not able to forecast the extent or duration of COVID-19’s effect on our small business in 2021, we are fired up about our modern enlargement into the immune reaction sector.”

Mr. Lubniewski continued, “We also continue to be really concentrated on our 20,000 in addition gene full transcriptome item that is in advancement and have executed quite a few letters of intent with prospective collaborators for our early access program in December 2020. We appear ahead to functioning with these companies and feel, with this solution, we will have a effective initial products start, now on observe for the third quarter of 2021. We imagine we have used 2020 to fortify the organization and established the phase for profits advancement in 2021.”

The preliminary outcomes established forth earlier mentioned are unaudited, are dependent on management’s preliminary assessment of the company’s effects as of and for the 12 months finished December 31, 2020 and are subject to revision primarily based on the company’s yr-close closing treatments and the completion and exterior audit of the firm’s yr-conclusion money statements. Actual benefits may well differ materially from these preliminary unaudited effects as a consequence of the completion of calendar year-stop closing treatments, final adjustments and other developments arising amongst now and the time that firm’s monetary effects are finalized, and these kinds of adjustments could be substance. In addition, these preliminary unaudited outcomes are not a comprehensive statement of the company’s financial outcomes for the 12 months ended December 31, 2020, should really not be viewed as a substitute for full, audited money statements ready in accordance with typically acknowledged accounting rules, and are not automatically indicative of the firm’s benefits for any long term time period.

The enterprise expects to announce complete 2020 financial benefits in progress of its quarterly conference simply call in March 2021.

About HTG:
HTG is centered on NGS-dependent molecular profiling. The firm’s proprietary HTG EdgeSeq technologies automates complex, extremely multiplexed molecular profiling from reliable and liquid samples, even when confined in sum. HTG’s customers use its technological know-how to discover biomarkers important for precision drugs, to realize the medical relevance of these discoveries, and ultimately to determine treatment solutions. Its mission is to empower precision medicine.

Harmless Harbor Statement:
Statements contained in this push release regarding matters that are not historic details are “ahead-seeking statements” inside of the meaning of the Private Securities Litigation Reform Act of 1995, such as statements pertaining to our envisioned income and other expected economic final results as of and for the 12 months finished December 31, 2020, and about our intention to create and start a entire transcriptome item, our expectation that letters of intent for our total transcriptome product or service will final result in us doing business with the counterparty organizations, our envisioned original whole transcriptome item start becoming profitable and developing in the 3rd quarter of 2021, and our belief that we will have revenue growth in 2021. Phrases these as “imagine,” “assume,” “will,” “potential,” “look ahead to,” “on observe for” and similar expressions are meant to recognize ahead-looking statements, even though not all ahead-hunting statements necessarily comprise these figuring out phrases. These ahead-looking statements are centered upon management’s present anticipations, are issue to regarded and unidentified dangers, and include assumptions that may never materialize or may possibly verify to be incorrect. Actual success and the timing of functions could differ materially from all those predicted in this sort of ahead-on the lookout statements as a end result of numerous challenges and uncertainties, including, with no limitation, the danger that our true income or other money effects for the whole calendar year 2020 may well differ materially from those set forth in this press launch as a outcome of the completion of yr-conclude closing strategies, final adjustments, or other developments arising among now and the time that our money benefits are finalized pitfalls related with our skill to efficiently commercialize our merchandise the chance that our products and solutions and expert services might not be adopted by biopharmaceutical firms or other customers as predicted, or at all our capability to manufacture our items to meet demand the stage and availability of reimbursement for our products and solutions our potential to defend our intellectual assets rights and proprietary technologies our ability to run our business devoid of infringing the mental property rights and proprietary know-how of 3rd functions competitors in our marketplace further funds and credit history availability our means to attract and retain certified personnel and product or service liability statements. These and other things are explained in larger depth in our filings with the Securities and Exchange Commission, which include without having limitation our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. All forward-on the lookout statements contained in this push launch converse only as of the day on which they ended up designed, and we undertake no obligation to update this sort of statements to mirror situations that manifest or situation that exist immediately after the date on which they have been created.

Get in touch with:
Ashley R. Robinson
LifeSci Advisors, LLC
Mobile phone: (617) 430-7577
Electronic mail:

Primary Logo